April 3 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Amgen's AMGN.O drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
(Reporting by Siddhi Mahatole, Mariam Sunny and Puyaan Singh in Bengaluru and Deena Beasley in Los Angeles; Editing by Alan Barona)
((siddhi.mahatole@thomsonreuters.com))